Embryonic stem cell factors and pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 9, 2014, Pages 2247-2254

  Herreros Villanueva, Marta ^a,b   Bujanda, Luis ^b   Billadeau, Daniel D ^a   Zhang, Jin San ^a,c  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Embryonic stem cells; NANOG; OCT4; Pancreatic cancer; Pluripotency; SOX2

Indexed keywords

DNA BINDING PROTEIN; HAND1 PROTEIN; HOXB1 PROTEIN; ISL1 PROTEIN; KRUPPEL LIKE FACTOR 4; LHX5 PROTEIN; MESDC1 PROTEIN; MESDC2 PROTEIN; MYOD1 PROTEIN; MYOGENIC FACTOR 5; NES PROTEIN; NEUROGENIC DIFFERENTIATION FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; ONECUT1 PROTEIN; OTX1 PROTEIN; PEPTIDES AND PROTEINS; STEM CELL FACTOR; TPBPA PROTEIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DNA METHYLATION; DNA REPAIR; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; HISTONE MODIFICATION; HUMAN; IMMUNOREACTIVITY; INNER CELL MASS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SURVIVAL RATE; ANIMAL; CANCER STEM CELL; CARCINOMA, PANCREATIC DUCTAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; DRUG DESIGN; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84895858886     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i9.2247     Document Type: Article

References (71)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/ caac.21166]
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
3. Kumar-Sinha C, Wei I, Simeone DM. Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. Curr Opin Gastroenterol 2012; 28: 516-522 [PMID: 22759592 DOI: 10.1097/MOG.0b013e3283567f69]
4. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 7: 64 [PMID: 18652674 DOI: 10.1186/1476-4598-7-64]
5. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227. e5 [PMID: 21864475 DOI: 10.1053/ j.gastro.2011.08.009]
6. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037 [PMID: 17283135 DOI: 10.1158/0008-5472.CAN-06-2030]
7. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323 [PMID: 18371365 DOI: 10.1016/j.stem.2007.06.002]
8. Ottinger S, Klöppel A, Rausch V, Liu L, Kallifatidis G, Gross W, Gebhard MM, Brümmer F, Herr I. Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract. Int J Cancer 2012; 130: 1671-1681 [PMID: 21544815 DOI: 10.1002/ijc.26168]
9. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett 2013; 338: 94-100 [PMID: 22445908 DOI: 10.1016/ j.canlet.2012.03.018]
10. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009; 125: 2323-2331 [PMID: 19598259 DOI: 10.1002/ijc.24573]
11. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet 2007; 8: 263-271 [PMID: 17363975 DOI: 10.1038/nrg2046]
12. Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles ME, Diaz-Rodriguez E, Garcia-Rendueles AR, Perez-Romero S, Vila TV, Rodrigues JS, Lear PV, Bravo SB. Defining stem cell types: understanding the therapeutic potential of ESCs, ASCs, and iPS cells. J Mol Endocrinol 2012; 49: R89-111 [PMID: 22822049 DOI: 10.1530/JME-12-0072]
13. Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 2007; 128: 747-762 [PMID: 17320511 DOI: 10.1016/j.cell.2007.02.010]
14. Xi R, Xie T. Stem cell self-renewal controlled by chromatin remodeling factors. Science 2005; 310: 1487-1489 [PMID: 16322456 DOI: 10.1126/science.1120140]
15. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-642 [PMID: 12787504]
16. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or selfrenewal of ES cells. Nat Genet 2000; 24: 372-376 [PMID: 10742100 DOI: 10.1038/74199]
17. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]
18. Tang F, Barbacioru C, Bao S, Lee C, Nordman E, Wang X, Lao K, Surani MA. Tracing the derivation of embryonic stem cells from the inner cell mass by single-cell RNA-Seq analysis. Cell Stem Cell 2010; 6: 468-478 [PMID: 20452321 DOI: 10.1016/j.stem.2010.03.015]
19. Pera MF, Tam PP. Extrinsic regulation of pluripotent stem cells. Nature 2010; 465: 713-720 [PMID: 20535200 DOI: 10.1038/nature09228]
20. Fujikura J, Yamato E, Yonemura S, Hosoda K, Masui S, Nakao K, Miyazaki Ji J, Niwa H. Differentiation of embryonic stem cells is induced by GATA factors. Genes Dev 2002; 16: 784-789 [PMID: 11937486 DOI: 10.1101/gad.968802]
21. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872 [PMID: 18035408 DOI: 10.1016/ j.cell.2007.11.019]
22. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920 [PMID: 18029452 DOI: 10.1126/science.1151526]
23. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26: 101-106 [PMID: 18059259 DOI: 10.1038/nbt1374]
24. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009; 4: 16-19 [PMID: 19097958 DOI: 10.1016/j.stem.2008.11.014]
25. Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, Hao E, Schöler HR, Hayek A, Ding S. Generation of humaninduced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009; 27: 2992-3000 [PMID: 19839055 DOI: 10.1002/stem.240]
26. Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, Kim J, Zhang K, Ding S. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010; 7: 651-655 [PMID: 21112560 DOI: 10.1016/j.stem.2010.11.015]
27. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737 [PMID: 9212098]
28. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325 [PMID: 11756187]
29. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828 [PMID: 14522905]
30. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65: 4320-4333 [PMID: 15899824 DOI: 10.1158/0008-5472.CAN-04-3327]
31. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153-3161 [PMID: 17409422 DOI: 10.1158/0008-5472.CAN-06-4429]
32. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110 [PMID: 17122772 DOI: 10.1038/nature05372]
33. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978 [PMID: 17210912 DOI: 10.1073/pnas.0610117104]
34. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988 [PMID: 12629218 DOI: 10.1073/pnas.0530291100]
35. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320 [PMID: 18519691 DOI: 10.1158/0008-5472.CAN-08-0364]
36. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 14016-14021 [PMID: 19666525 DOI: 10.1073/ pnas.0906549106]
37. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835 [PMID: 15960971 DOI: 10.1016/ j.cell.2005.03.032]
38. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM, Bujanda L, Billadeau DD. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013; 2: e61 [PMID: 23917223 DOI: 10.1038/oncsis.2013.23]
39. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66: 1883-190; discussion 1883-190; [PMID: 16488983 DOI: 10.1158/0008-5472. CAN-05-3153]
40. Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013; 144: 1241-1248 [PMID: 23622133 DOI: 10.1053/j.gastro.2013.01.072]
41. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598 [PMID: 19052619 DOI: 10.1038/nature07567]
42. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507 [PMID: 18443585 DOI: 10.1038/ng.127]
43. Bernhardt M, Galach M, Novak D, Utikal J. Mediators of induced pluripotency and their role in cancer cells-current scientific knowledge and future perspectives. Biotechnol J 2012; 7: 810-821 [PMID: 22589234 DOI: 10.1002/ biot.201100347]
44. Pei D. Regulation of pluripotency and reprogramming by transcription factors. J Biol Chem 2009; 284: 3365-3369 [PMID: 18819918 DOI: 10.1074/jbc.R800063200]
45. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011; 6: e20636 [PMID: 21695188 DOI: 10.1371/journal.pone.0020636]
46. Van den Broeck A, Vankelecom H, Van Delm W, Gremeaux L, Wouters J, Allemeersch J, Govaere O, Roskams T, Topal B. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PLoS One 2013; 8: e73968 [PMID: 24069258 DOI: 10.1371/ journal.pone.0073968]
47. Polvani S, Tarocchi M, Tempesti S, Mello T, Ceni E, Buccoliero F, D'Amico M, Boddi V, Farsi M, Nesi S, Nesi G, Milani S, Galli A. COUP-TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression. Int J Cancer 2014; 134: 1648-1658 [PMID: 24122412 DOI: 10.1002/ijc.28502]
48. Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, Ishida T, Ohuchi N, Sasano H. Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 2009; 100: 639-645 [PMID: 19154418]
49. Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, Song SY. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010; 39: 622-626 [PMID: 20173672 DOI: 10.1097/MPA.0b013e3181c75f5e]
50. Lu Y, Zhu H, Shan H, Lu J, Chang X, Li X, Lu J, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y, Zhu M, Wang Z. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett 2013; 340: 113-123 [PMID: 23872274 DOI: 10.1016/j.canlet.2013.07.009]
51. Quint K, Tonigold M, Di Fazio P, Montalbano R, Lingelbach S, Rückert F, Alinger B, Ocker M, Neureiter D. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int J Oncol 2012; 41: 2093-2102 [PMID: 23026911 DOI: 10.3892/ijo.2012.1648]
52. Wang D, Zhu H, Zhu Y, Liu Y, Shen H, Yin R, Zhang Z, Su Z. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stemlike cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem 2013; 115: 349-356 [PMID: 23036582 DOI: 10.1016/ j.acthis.2012.09.007]
53. Wang X, Liu Q, Hou B, Zhang W, Yan M, Jia H, Li H, Yan D, Zheng F, Ding W, Yi C. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One 2013; 8: e73942 [PMID: 24040121 DOI: 10.1371/journal. pone.0073942]
54. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 2006; 32: 164-170 [PMID: 16552336 DOI: 10.1097/01. mpa.0000202947.80117.a0]
55. Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, Schnidar H, Hache H, Bauer HC, Solca F, Hauser-Kronberger C, Ermilov AN, Verhaegen ME, Bichakjian CK, Dlugosz AA, Nietfeld W, Sibilia M, Lehrach H, Wierling C, Aberger F. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012; 4: 218-233 [PMID: 22294553 DOI: 10.1002/emmm.201100201]
56. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res 2012; 18: 4277-4284 [PMID: 22896694 DOI: 10.1158/1078-0432.CCR-11-3112]
57. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, Houchen CW. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One 2013; 8: e73940 [PMID: 24040120 DOI: 10.1371/journal.pone.0073940]
58. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17: 126-140 [PMID: 12514105 DOI: 10.1101/gad.224503]
59. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-655 [PMID: 12787505]
60. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL, Ruan Y, Lim B, Ng HH. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006; 38: 431-440 [PMID: 16518401 DOI: 10.1038/ng1760]
61. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242 [PMID: 19801978 DOI: 10.1038/ng.465]
62. Cox JL, Wilder PJ, Desler M, Rizzino A. Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One 2012; 7: e44087 [PMID: 22937156 DOI: 10.1371/journal.pone.0044087]
63. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31: 1354-1365 [PMID: 21822303 DOI: 10.1038/onc.2011.338]
64. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446 [PMID: 22056140 DOI: 10.1016/ j.stem.2011.10.001]
65. Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013; 4: e627 [PMID: 23661005 DOI: 10.1038/cddis.2013.158]
66. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014; 146: 245-256 [PMID: 24096005]
67. Sobrevals L, Mato-Berciano A, Urtasun N, Mazo A, Fillat C. uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors. Stem Cell Res 2014; 12: 1-10 [PMID: 24141108]
68. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 2013; 8: e76518 [PMID: 24204632 DOI: 10.1371/journal.pone.0076518]
69. Kim SK, Kim H, Lee DH, Kim TS, Kim T, Chung C, Koh GY, Kim H, Lim DS. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS One 2013; 8: e78130 [PMID: 24194908 DOI: 10.1371/journal.pone.0078130]
70. Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 2013; 8: e61532 [PMID: 23650499 DOI: 10.1371/journal. pone.0061532]
71. Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS, Xu L. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res 2013; 19: 6703-6715 [PMID: 24132924 DOI: 10.1158/1078-0432. CCR-13-0621]